For instance, the common gain of function mutation in the LPL (lipoprotein lipase) gene, a well-known CAD locus included in the CAD-PGRS based on 204 SNPs, has been found to influence the cardiovascular effectiveness of fenofibrate [35]—a PPAR-alpha agonist with known effects on LPL expression and lipoprotein lipase activity [36]. This evidence concerns the gene LPL and coronary artery disorder.